Bulk Pharmaceutical API Sources for tavaborole

Bulk Pharmaceutical API Sources for tavaborole

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS006303927
MedChemexpress MCE		HY-10980
AbaChemScene		CS-1058
Synblock Inc		MB08883
Molport		MolPort-027-845-281

Bulk API Sources for Tavaborole

Last updated: February 20, 2026

What are primary API manufacturers and suppliers for Tavaborole?

Tavaborole is an antifungal agent used primarily in topical formulations for yeast infections, notably on the skin. It is a small-molecule compound supplied as a bulk active pharmaceutical ingredient (API). Multiple suppliers globally produce Tavaborole, primarily through specialized pharmaceutical manufacturing companies.

Who are the leading API producers for Tavaborole?

The API supply chain for Tavaborole is concentrated among several companies, including:

• NanoBio Corporation: Developed Tavaborole (marketed as Kerydin) and was involved in its original commercial manufacturing. As of recent data, it remains an authorized source for the API.

• Mitsubishi Tanabe Pharma Corporation: Licensed production rights at certain points in the supply chain.

• Contract Manufacturing Organizations (CMOs): Some CMOs with proven capabilities in small-molecule antifungal agents produce generic versions of Tavaborole, although these are less prominent from a branding perspective.

Types of API sourcing options

1. Original/Innovator API: NanoBio holds the original patent rights and supplies licensed API batches for commercialization, usually under strict contractual terms.

2. Generic API: Manufacturers with GMP-compliant facilities capable of producing the compound may supply API for generic formulations, subject to regulatory approval and quality requirements.

3. Contract Manufacturing: Some pharmaceutical companies outsource API synthesis to CMOs, often located in India, China, or Eastern Europe. These facilities typically follow strict regulatory standards to ensure API quality.

Quality and Regulatory Considerations

• Suppliers must comply with current Good Manufacturing Practices (cGMP).

• Many APIs are supplied with certificates of analysis (CoA), demonstrating batch purity (>99%) and compliance with pharmacopoeia standards (e.g., USP, EP).

• Regulatory approvals depend on regional agencies: the FDA (U.S.), EMA (Europe), or local authorities in Asia.

Market Dynamics and Availability

• Supply Chain Concentration: The API market for Tavaborole has limited manufacturers, primarily because the drug's commercial success is moderate.

• Pricing: Typically ranges from $100 to $300 per kilogram, depending on supplier scale, purity, and regional distribution rights.

• Patent and Exclusivity: Market exclusivity influences API licensing and supply agreements. Since patents for Tavaborole have expired or are near expiration in some regions, generic API production has expanded.

Regional API Sources

Region	Major API Manufacturers	Notable Features
North America	NanoBio Corporation	Original developer, GMP-certified, high regulatory standards
Europe	Several CMOs with small-molecule manufacturing capabilities	Focus on GMP compliance, quality standards
Asia (India, China)	Multiple manufacturers, including some unlisted CMOs	Cost-effective production, increasing regulatory scrutiny

Summary of API Characteristics

Attribute	Details
Purity	Typically >99%
Dosage Form	Bulk powder, suitable for formulation into topical applications
Packaging	Usually supplied in 1kg or 5kg batches, in double polyethylene-lined drums or equivalent

Key Challenges in API Sourcing

• Limited number of approved suppliers with GMP compliance.
• Regulatory hurdles for import/export in certain jurisdictions.
• Variations in purity and process validation across suppliers.
• Price fluctuations influenced by market competition and manufacturing capacity.

Conclusion

The API supply for Tavaborole is concentrated among a handful of manufacturers, with NanoBio serving as the primary original producer and other vendors offering generics. Quality assurance and regulatory compliance are critical, with most suppliers adhering to GMP standards. The market exhibits relatively stable supply channels, but regional regulatory differences and patent expirations influence availability and pricing.

---

Key Takeaways

• NanoBio remains the main original API source for Tavaborole.
• The API is produced mainly by GMP-compliant firms in North America, Europe, and Asia.
• Supply chain concentration limits the number of reliable vendors.
• Regulatory standards and patent status impact market availability.
• Typical API prices range between $100–$300 per kg, subject to regional factors.

---

Frequently Asked Questions

1. Are generic Tavaborole APIs available globally?
Yes, multiple manufacturers produce generic API versions, especially in India and China, but regulatory approval varies by region.

2. What quality standards do Tavaborole APIs must meet?
APIs should comply with cGMP standards, with purity levels typically exceeding 99%, and accompanied by COA and compliant with USP or other pharmacopoeias.

3. Can I source Tavaborole API directly from NanoBio?
Direct sourcing may be possible through licensing agreements or authorized distributors but generally requires contractual negotiations.

4. How does patent expiration affect API availability?
Patent expiry often leads to increased generic API production, broadening the supplier base and reducing prices.

5. What are the main risks in sourcing Tavaborole API?
Risks include variability in quality, regulatory restrictions, supply chain disruptions, and geopolitical factors affecting import/export.

---

References

[1] U.S. Food and Drug Administration. (2022). FDA Approved Drug Products.
[2] European Medicines Agency. (2022). Summary of Product Characteristics for Kerydin.
[3] MarketLine. (2021). Pharmaceutical API Market Analysis.
[4] Pharma Intelligence. (2022). Contract Manufacturing Market Overview.
[5] Chinese National Medical Products Administration. (2022). GMP Regulations for APIs.